TScan Therapeutics Inc (TCRX)

[FACT-MASTER]

TCRX First presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting is today 5:30 - 6:30 p.m.

https://ca.finance.yahoo.com/news/tscan-therapeutics-announces-upcoming-presentations-210200326.html

Title: Discovery of TSC-200-A02: A natural HPV16 E7-specific TCR-T cell therapy candidate for the treatment of HPV-positive solid tumors
Presenter: Gavin MacBeath
Poster Number: M-198
Abstract Number: 317
Session: Cancer – Immunotherapy, Cancer Vaccines I
Date & Time: Monday, May 16, 2022 5:30-6:30 p.m. ET
Location: Hall D

Summary: Human papilloma virus (HPV)16 E7 oncoprotein is homogenously expressed in every tumor cell of HPV16 positive tumors, is essential for tumor cell survival, and is not expressed by healthy tissues. Using TScan’s proprietary ReceptorScan platform, the Company identified a lead TCR. The lead TCR showed comparable preclinical activity to a therapeutic TCR from NCI, that has previously shown a 50% objective response rate in a Phase I clinical trial. No allo-reactivity was observed for the HLAs tested and only a few putative off-targets were identified using our genome-wide SafetyScan platform. The lead TCR showed no reactivity to primary healthy tissues expressing these putative off-targets during in vitro co-culture experiments indicating minimal off-tumor reactivity risk. To further enhance the function of the therapeutic T cell product, TScan is designing a transposon-based vector that can deliver the TCR gene, along with the genes for CD8a/ß and dominant-negative form of TGFßRII, into both CD4+ and CD8+ T cells. The resulting TCR-T cell therapy candidate, TSC-200-A02, is expected to complete IND-enabling studies in the second half of 2022. These results validate the use of ReceptorScan and SafetyScan as a way to rapidly identify naturally occurring, high affinity TCRs suitable for clinical development.